Francis Dailey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Francis Dailey has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Erica P. Turse
Department of Medicine, Creighton University School of Medicine Program, Phoenix, AZ, USA
3 shared publications - Veysel Tahan
Charleston Area Medical Center, Charleston, WV 25304, USA
3 shared publications - Amber R Howard
Cedars-Sinai Medical Center, Health Services Research, Los Angeles,CA, CA, United States
1 shared publication - Bibiana Martinez
Cedars-Sinai Medical Center, Health Services Research, Los Angeles,CA, CA, United States
1 shared publication - Bradley Todd Rosen
Cedars-Sinai Medical Center, Health Services Research, Los Angeles,CA, CA, United States
1 shared publication Brennan M.R. Spiegel
Department of Gastroenterology, VA Greater Los Angeles Healthcare System, Los Angeles, California, USA; Cedars-Sinai Center for Outcomes Research and Education, Los Angeles, California, USA; Department of Health Policy and Management, University of California, Los Angeles Fielding School of Public Health, Los Angeles, California, USA
1 shared publication
Latest Publications
- 1 December 2019
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 49, 29-33
The dirty aspects of fecal microbiota transplantation: a review of its adverse effects and complications
- 1 December 2019
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 49, 29-33
The dirty aspects of fecal microbiota transplantation: a review of its adverse effects and complications
- 1 December 2019
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 49, 24-28
Fecal microbiota transplantation donation: the gift that keeps on giving
- 1 December 2019
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 49, 24-28
Fecal microbiota transplantation donation: the gift that keeps on giving
- Open Access
- 26 October 2018
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 6 (12) , 493-500
One more chance of fistula healing in inflammatory bowel disease: Stem cell therapy
Patients with fistulizing inflammatory bowel disease are traditionally difficult to treat. This patient population often experiences delayed or insufficient healing of fistulas using current standard regimens including antibiotics, immunomodulators, anti-tumor necrosis factor-α drug, placement of setons, and surgical repair. Several studies over the last ten to fifteen years have been conducted using stem cell therapies with promising results in this patient population. These studies show stem cell therapy in fistulizing disease to be successful in healing between 60%-88% compared to currently 50% with infliximab. Moreover, remission was seen 24 wk to 52 wk in these studies. Further research with a multi-approach treatment using medications, stem cell therapy, and surgical interventions will likely be the future of this innovative treatment approach.
- 26 October 2018
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 6 (12) , 493-500
Open AccessOne more chance of fistula healing in inflammatory bowel disease: Stem cell therapy
Patients with fistulizing inflammatory bowel disease are traditionally difficult to treat. This patient population often experiences delayed or insufficient healing of fistulas using current standard regimens including antibiotics, immunomodulators, anti-tumor necrosis factor-α drug, placement of setons, and surgical repair. Several studies over the last ten to fifteen years have been conducted using stem cell therapies with promising results in this patient population. These studies show stem cell therapy in fistulizing disease to be successful in healing between 60%-88% compared to currently 50% with infliximab. Moreover, remission was seen 24 wk to 52 wk in these studies. Further research with a multi-approach treatment using medications, stem cell therapy, and surgical interventions will likely be the future of this innovative treatment approach.
- 1 April 2017
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 85 (4) , 700-705
Predictive overbooking and active recruitment increases uptake of endoscopy appointments among African American patients
- 1 April 2017
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 85 (4) , 700-705
Predictive overbooking and active recruitment increases uptake of endoscopy appointments among African American patients
- Top Cited PapersOpen Access
- 29 March 2017
- Published by JMIR Publications Inc. in JMIR Mental Health
- Vol. 4 (1) , e9
Virtual Reality for Management of Pain in Hospitalized Patients: Results of a Controlled Trial
Background: Improvements in software and design and reduction in cost have made virtual reality (VR) a practical tool for immersive, three-dimensional (3D), multisensory experiences that distract patients from painful stimuli. Objective: The objective of the study was to measure the impact of a onetime 3D VR intervention versus a two-dimensional (2D) distraction video for pain in hospitalized patients. Methods: We conducted a comparative cohort study in a large, urban teaching hospital in medical inpatients with an average pain score of ≥3/10 from any cause. Patients with nausea, vomiting, dementia, motion sickness, stroke, seizure, and epilepsy and those placed in isolation were excluded. Patients in the intervention cohort viewed a 3D VR experience designed to reduce pain using the Samsung Gear Oculus VR headset; control patients viewed a high-definition, 2D nature video on a 14-inch bedside screen. Pre- and postintervention pain scores were recorded. Difference-in-difference scores and the proportion achieving a half standard deviation pain response were compared between groups. Results: There were 50 subjects per cohort (N=100). The mean pain reduction in the VR cohort was greater than in controls (−1.3 vs −0.6 points, respectively; P=.008). A total of 35 (65%) patients in the VR cohort achieved a pain response versus 40% of controls (P=.01; number needed to treat=4). No adverse events were reported from VR. Conclusions: Use of VR in hospitalized patients significantly reduces pain versus a control distraction condition. These results indicate that VR is an effective and safe adjunctive therapy for pain management in the acute inpatient setting; future randomized trials should confirm benefit with different visualizations and exposure periods. Trial Registration: Clinicaltrials.gov NCT02456987; https://clinicaltrials.gov/ct2/show/NCT02456987 (Archived by WebCite at http://www.webcitation.org/6pJ1P644S)
- 29 March 2017
- Published by JMIR Publications Inc. in JMIR Mental Health
- Vol. 4 (1) , e9
Top Cited PapersOpen AccessVirtual Reality for Management of Pain in Hospitalized Patients: Results of a Controlled Trial
Background: Improvements in software and design and reduction in cost have made virtual reality (VR) a practical tool for immersive, three-dimensional (3D), multisensory experiences that distract patients from painful stimuli. Objective: The objective of the study was to measure the impact of a onetime 3D VR intervention versus a two-dimensional (2D) distraction video for pain in hospitalized patients. Methods: We conducted a comparative cohort study in a large, urban teaching hospital in medical inpatients with an average pain score of ≥3/10 from any cause. Patients with nausea, vomiting, dementia, motion sickness, stroke, seizure, and epilepsy and those placed in isolation were excluded. Patients in the intervention cohort viewed a 3D VR experience designed to reduce pain using the Samsung Gear Oculus VR headset; control patients viewed a high-definition, 2D nature video on a 14-inch bedside screen. Pre- and postintervention pain scores were recorded. Difference-in-difference scores and the proportion achieving a half standard deviation pain response were compared between groups. Results: There were 50 subjects per cohort (N=100). The mean pain reduction in the VR cohort was greater than in controls (−1.3 vs −0.6 points, respectively; P=.008). A total of 35 (65%) patients in the VR cohort achieved a pain response versus 40% of controls (P=.01; number needed to treat=4). No adverse events were reported from VR. Conclusions: Use of VR in hospitalized patients significantly reduces pain versus a control distraction condition. These results indicate that VR is an effective and safe adjunctive therapy for pain management in the acute inpatient setting; future randomized trials should confirm benefit with different visualizations and exposure periods. Trial Registration: Clinicaltrials.gov NCT02456987; https://clinicaltrials.gov/ct2/show/NCT02456987 (Archived by WebCite at http://www.webcitation.org/6pJ1P644S)